Beaufour Ipsen to sell valsartan in France
Beaufour Ipsen has entered into an agreement with Aventis in which it will take over the promotion in France of the latter's range of products based on valsartan, an angiotensin II receptor antagonist. As of the end of March, Beaufour has been promoting the Nisis brand of valsartan and related product Nisisco (valsartan and hydrochlorothiazide) in France and all its territories, as well as the principalities of Andorra and Monaco.
Beaufour notes that, in 2002, Nisis and Nisisco had a turnover of more than 24 million euros ($28 million), bolstered by the launch of a new high-dose Nisisco formulation (160mg of valsartan and 25mg of hydrochlorothiazide) last February.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze